[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"primary-aldosteronism-due-to-aldosterone-producing-adenoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:primary-aldosteronism-due-to-aldosterone-producing-adenoma":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100615833","trial-of-aldosterone-hybrid-steroid-for-guiding-curable-treatment-of-primary-aldosteronism-target-pa-100615833",false,"NCT07297745","Trial of Aldosterone-hybrid SteRoid for Guiding curablE Treatment of Primary Aldosteronism (TARGET-PA)","Inclusion Criteria:\n\n* Confirmed diagnosis of primary aldosteronism according to the Endocrine Society guideline 2025.\n* Willing to undergo subtype testing with adrenal vein sampling and\u002For molecular imaging (Positron Emission Tomography\u002FComputed Tomography, PET\u002FCT).\n* Keen for surgical treatment if shown to have unilateral primary aldosteronism.\n\nExclusion Criteria:\n\n* Inability to provide written informed consent.","ALL","21 Years",{"count":18,"type":19},120,"ESTIMATED","INTERVENTIONAL",[22],"NA","The goal of this project is to improve the diagnostic pathway for patients with primary aldosteronism, by validating non-invasive biomarkers coupled with routine computed tomography imaging. The aim is to reduce reliance on invasive procedures, shorten diagnostic timelines, and enhance accessibility to definitive diagnosis and treatment globally.",[25,26],"Hyperaldosteronism; Primary","Primary Aldosteronism Due to Aldosterone Producing Adenoma",[28,29,30,31,32,33],"Hybrid hormone","Subtyping","adrenalectomy","adrenal vein sampling","biomarkers","steroid profiling","NOT_YET_RECRUITING","2026-01-07",{"date":37,"type":38},"2026-01-09","ACTUAL",{"date":40,"type":19},"2026-01-15",{"date":42,"type":19},"2029-12-31",{"name":44,"class":45},"Changi General Hospital","OTHER",4,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":15,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":20,"phases":58,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100575544","phase-1-application-of-al18f-nota-pentixafor-petct-for-primary-aldosteronism-100575544","NCT06773663","Application of Al18F-NOTA-Pentixafor PET\u002FCT for Primary Aldosteronism","Evaluation of Biodistribution, Dosimetry, Diagnostic and Surgery-guiding Ability of Al18F-NOTA-Pentixafor PET Imaging for Patients With Primary Aldosteronism: A Prospective, Single-center Study","Inclusion Criteria:\n\n1. Patients with adrenal masses suspected to be aldosterone-producing adenomas based on routine imaging (e.g., CT scans), or clinically diagnosed primary aldosteronism patients requiring subtyping\n2. Signed written informed consent, with willingness and ability to comply with study procedures.\n3. Female participants must be surgically sterilized or postmenopausal for over a year; if not, reliable contraception is required.\n4. Male participants must use reliable contraception during the study and refrain from sperm donation.\n\nExclusion Criteria:\n\n1. Severe neurological disorders, or any significant diseases affecting the gastrointestinal, cardiovascular, hepatic, renal, hematological, oncological, endocrine, respiratory, or immune systems, or other serious illnesses.\n2. Diagnosis of claustrophobia.\n3. History of drug abuse or alcohol dependence.\n4. Pregnant or breastfeeding women.\n5. Poor venous access that would preclude repeated venipuncture.\n6. Use of experimental drugs or devices within one month prior to the study, where the safety or efficacy has not been established.\n7. Any condition that the study investigators deem could pose potential harm or jeopardize participant safety.","18 Years","80 Years",{"count":57,"type":19},150,[59,60],"PHASE1","PHASE2","This prospective, single-center study investigates the biodistribution, dosimetry, safety, diagnostic performance of Al18F-NOTA-Pentixafor PET imaging in patients with primary aldosteronism. And evaluates the potential of Al18F-NOTA-Pentixafor PET imaging in surgical strategy guidance.",[63,26],"Primary Aldosteronism","RECRUITING","2025-02-25",{"date":67,"type":38},"2025-02-26",{"date":69,"type":38},"2023-12-30",{"date":71,"type":19},"2026-10-30",{"name":73,"class":45},"Peking Union Medical College Hospital",1]